



Supporters of the **Drug Competition Enhancement Act** claim that companies engage in so-called “product hopping” — deterring generic competition by stopping production of an outdated drug once they patent a new one.

But the truth is that **every** industry retires old models.

What if phone and automobile manufacturers continued making older models when newer, safer, and more reliable ones exist?

**Of course not.** Competitors would drive them out of business. This isn't malicious — **it's** innovation at work.



Improvements to a patented drug don't reset the clock — once the original patent or exclusivity period ends, generic manufacturers are free to enter the market.

**This bill won't boost competition — it will kill it.**

**Without strong patent protections, there's no incentive to innovate.  
Without innovation, everyone loses.**